These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2361582)

  • 1. [Principles of treatment with iron chelates].
    Gershko Kh; Link D; Pinson A
    Gematol Transfuziol; 1990 Mar; 35(3):13-5. PubMed ID: 2361582
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 3. Iron Chelation for Iron Overload in Thalassemia.
    Crisponi G; Nurchi VM; Lachowicz JI
    Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings of the 18th International Conference on Chelation (ICOC). December 13-16, 2008, Athens, Greece.
    Hemoglobin; 2010 Jun; 34(3):199-331. PubMed ID: 21305716
    [No Abstract]   [Full Text] [Related]  

  • 5. An oral treatment for iron overload in thalassemia?
    Kowdley KV; Tavill AS
    Hepatology; 1996 Feb; 23(2):380-2. PubMed ID: 8591869
    [No Abstract]   [Full Text] [Related]  

  • 6. Do we need more iron-chelating drugs?
    Kontoghiorghes GJ
    Lancet; 2003 Aug; 362(9382):495-6. PubMed ID: 12927446
    [No Abstract]   [Full Text] [Related]  

  • 7. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 8. Proceedings of the 17th International Conference on Chelation (ICOC) for the Treatment of Thalassemia, Cancer and Other Diseases Related to Metal and Free Radical Imbalance and Toxicity. November 2007. Shenzhen, China.
    Hemoglobin; 2009; 33(5):283-397. PubMed ID: 20052787
    [No Abstract]   [Full Text] [Related]  

  • 9. Pituitary somatotropic and corticotropic function in patients with beta-thalassemia on iron chelation therapy.
    Tolis G; Politis C; Kontopoulou I; Poulatzas N; Rigas G; Saridakis C; Athanasiou V; Mortoglou A; Malachtari S; Ling N
    Birth Defects Orig Artic Ser; 1987; 23(5A):449-52. PubMed ID: 3120817
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spleen iron content is low in thalassemia.
    Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
    Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
    Kontoghiorghes GJ; Spyrou A; Kolnagou A
    Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Deferiprone in Iron Chelation.
    Hider RC; Hoffbrand AV
    N Engl J Med; 2018 Nov; 379(22):2140-2150. PubMed ID: 30485781
    [No Abstract]   [Full Text] [Related]  

  • 16. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.
    Evangeli M; Mughal K; Porter JB
    Hemoglobin; 2010 Jun; 34(3):305-21. PubMed ID: 20524820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Management of Patients With Thalassemia Syndromes.
    Martin M; Haines D
    Clin J Oncol Nurs; 2016 Jun; 20(3):310-7. PubMed ID: 27206298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassaemia.
    Chuansumrit A; Pengpis P; Mahachoklertwattana P; Sirachainan N; Poomthavorn P; Sungkarat W; Kadegasem P; Khlairit P; Wongwerawattanakoon P
    Acta Haematol; 2017; 137(1):20-26. PubMed ID: 27838686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron Chelation Therapy as a Modality of Management.
    Aydinok Y
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].
    Efendieva EG; Dashkova NG
    Gematol Transfuziol; 1987 Sep; 32(9):23-6. PubMed ID: 3692120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.